Advanced Prostate Cancer Clinical Trial
Official title:
PRORAD-5 PROstate RADiation in 5 Fractions: Phase Ib Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer
To look at the safety and effectiveness of stereotactic body radiation therapy (SBRT) in treating advanced or high-risk prostate cancer.
Status | Not yet recruiting |
Enrollment | 70 |
Est. completion date | September 1, 2027 |
Est. primary completion date | September 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Pathologically (histologically or cytologically) proven diagnosis of adenocarcinoma of prostate within one year of study entry. Evaluation can happen outside of MD Anderson as long as histological confirmation takes place at MD Anderson. 1. cT1c-T3a by digital exam or imaging (AJCC 8th Ed.). No cT3b-4 by digital exam or imaging (AJCC 8th Ed.) 2. Gleason Grade Group 2-5 (Gleason 7, 8, 9, 10). 3. If Gleason Grade 2, must meet definition of unfavorable intermediate risk (at least one of the following: cT2b, PSA >10 ng/mL prior to starting androgen deprivation therapy (ADT). If a participant is taking 5-alpha reductase inhibitors the measured PSA may be doubled). 2. Node negative by conventional imaging. 3. Be = 18 years of age on the day of signing informed consent. 4. Prior pharmacologic androgen ablation for prostate cancer is allowed only if the onset of androgen ablation (both LHRH agonist and oral anti-androgen) is = 185 days prior to registration; Please note: baseline PSA must be obtained prior to the start of any ADT. 5. ECOG performance status 0-2. Exclusion Criteria: 1. Diagnosis of active scleroderma, lupus, or other rheumatologic disease which in the opinion of the treating radiation oncologist precludes safe RT. 2. Prior prostatectomy, cryosurgery, or HIFU for adenocarcinoma of the prostate 3. Prior radiotherapy to the region of the study cancer that would result in overlap of radiation fields 4. Distant metastatic disease on conventional imaging, which by the discretion of the treating physician cannot be treated definitively. |
Country | Name | City | State |
---|---|---|---|
United States | MD Anderson Cancer Center | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
M.D. Anderson Cancer Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety and adverse events (AEs) | Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 | Through study completion; an average of 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06006104 -
Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03936218 -
Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer
|
Phase 3 | |
Completed |
NCT02234089 -
Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.
|
||
Completed |
NCT01078545 -
Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS)
|
N/A | |
Active, not recruiting |
NCT03511196 -
Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer
|
Early Phase 1 | |
Recruiting |
NCT05942001 -
Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
|
Phase 1 | |
Active, not recruiting |
NCT04117594 -
Whole Body Magnetic Resonance Imaging Study
|
||
Completed |
NCT01383863 -
A Long-term Observational Study Cohort in Patients With Advanced Prostate Cancer
|
||
Completed |
NCT03651271 -
Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT05590793 -
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate
|
Phase 3 | |
Recruiting |
NCT06095089 -
A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer
|
Phase 1 | |
Active, not recruiting |
NCT02787837 -
PROSABI: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Abiraterone Acetate.
|
||
Active, not recruiting |
NCT02362620 -
PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel.
|
||
Recruiting |
NCT05800665 -
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
|
Phase 1 | |
Recruiting |
NCT03938649 -
SRAM study_Postate Cancer
|
Phase 2 | |
Completed |
NCT00871585 -
Evaluation of Prostate-Specific Antigen (PSA) Levels in Patients With Advanced Prostate Cancer Treated With Bicalutamide
|
N/A | |
Active, not recruiting |
NCT02922218 -
PROSENZA: Prospective Multi-Centre Study of Prognostic Factors in mCRPC Patients Treated With Enzalutamide.
|
||
Not yet recruiting |
NCT06335914 -
Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer
|
N/A | |
Terminated |
NCT03577028 -
Study of HPN424 in Patients With Advanced Prostate Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT03971110 -
A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy.
|
Phase 4 |